Cytokine changes during rituximab therapy in HIV-associated multicentric Castleman disease
Cytokine changes during rituximab therapy in HIV-associated multicentric Castleman disease
复制标题
DOI：
10.1182/blood-2008-12-197053
复制
发表时间：
2009-05-07
期刊：
影响因子：
20.3
通讯作者：
Stebbing, Justin
中科院分区：
文献类型：
--
作者：
Bower, Mark;Veraitch, Ophelia;Stebbing, Justin
最近的数据强调了炎症标志物在人类免疫缺陷病毒1型（HIV）感染中的重要性。hiv相关的多中心Castleman病（HIV-MCD）表现出归因于细胞因子紊乱的全身性症状，我们之前的研究表明，使用抗cd20单克隆抗体利妥昔单抗可诱导临床缓解。在利妥昔单抗治疗成功之前和期间，测量了15种血浆细胞因子，包括适应性（CD4, CD8, CD19）和先天（CD16/56）免疫细胞群和HIV-1病毒载量。观察到CD19 b细胞计数从基线显著减少，与利妥昔单抗的作用机制一致。在利妥昔单抗治疗前观察到细胞因子水平明显升高，并且在利妥昔单抗治疗后观察到白细胞介素(IL)-5、IL-6和IL-10的基线值下降。减少炎症细胞因子反应的疗法可能在包括HIV-MCD在内的一系列疾病中取得成功，未来可能用于指导治疗策略。(血。2009;113:4521 - 4524)
Recent data highlight the importance of inflammatory markers during human immunodeficiency virus type 1 (HIV) infection. HIV-associated multicentric Castleman disease (HIV-MCD) presents with systemic symptoms attributed to cytokine disarray, and we have previously shown that the use of the anti-CD20 monoclonal antibody rituximab induces clinical remissions. Before and during successful rituximab therapy, 15 plasma cytokines were measured as were adaptive (CD4, CD8, CD19) and innate (CD16/56) immune cell populations and HIV-1 viral loads. A significant reduction from baseline of the CD19 B-cell count, consistent with rituximab's mechanism of action, was observed. Markedly elevated cytokine levels were observed before rituximab therapy, and a reduction from baseline values with rituximab therapy was observed for interleukin (IL)-5, IL-6, and IL-10. Therapies that reduce the inflammatory cytokine response are likely to be successful in a range of diseases, including HIV-MCD, and in the future may be used to guide therapeutic strategies. (Blood. 2009;113:4521-4524)